Inventor · disambiguated record
David Koos
Also filed as: KOOS DAVID · KOOS DAVID R
11 granted patents·19 pending applications·10 citations·filing 2013–2024
83Inventor score
Top patents by PatentIndex Score
30 records- 0184US11141471B2Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cellsREGEN BIOPHARMA INC·Filed 2017·Granted Oct 12, 2021·3 cites·13 claims
- 0282US11090332B2Antigen specific mRNA cellular cancer vaccinesREGEN BIOPHARMA INC·Filed 2016·Granted Aug 17, 2021·2 cites·13 claims
- 0378US10472351B2Small molecule agonists and antagonists of NR2F6 activity in animalsZANDER THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·2 cites·3 claims
- 0476US11241427B2Small molecule modulators of NR2F6 activityREGEN BIOPHARMA INC·Filed 2016·Granted Feb 8, 2022·1 cites·9 claims
- 0576US11053503B2Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibitionREGEN BIOPHARMA INC·Filed 2017·Granted Jul 6, 2021·1 cites·8 claims
- 0671US11324719B2Small molecule agonists and antagonists of NR2F6 activity in humansKCL THERAPEUTICS INC·Filed 2017·Granted May 10, 2022·1 cites·3 claims
- 0770US2025059507A1Generation of Tolerance Promoting CAR-T Cells by Enhancement of NR2F6REGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 0866US2024093205A1Dual checkpoint inhibitor aptamer based therapeuticsREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 0965US2024366760A1Activation of survivin-specific immune responses using dendritic cell derived exosomesREGEN BIOPHARMA INC·Filed 2024·Application pending·0 cites
- 1064US2024024443A1Augmentation of survivin modified mrna vaccine efficacy using dendritic cellsREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1163US11655474B2Suppression of pathological angiogenesis by inhibition of NR2F6REGEN BIOPHARMA INC·Filed 2020·Granted May 23, 2023·0 cites·2 claims
- 1263US2024100160A1Enhancement of t cell homing to tumors through augmentation of chemokine responsiveness and activation dependent chemokine secretionREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1363US2024165204A1Modulation of tumor microenvironment to augment efficacy of immunotherapyREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1462US10716810B2Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytesZANDER THERAPEUTICS INC·Filed 2018·Granted Jul 21, 2020·0 cites·1 claims
- 1562US2024066126A1Combination therapy of solid tumors using chimeric antigen receptor cells representing adaptive and innate immunityREGEN BIOPHARMA INC·Filed 2023·Application pending·0 cites
- 1659US11712474B2Reduction of post-surgery cancer metastasis by combination of cannabidiol and NR2F6 inhibitionREGEN BIOPHARMA INC·Filed 2020·Granted Aug 1, 2023·0 cites·19 claims
- 1757US2022249436A1Small Molecule Agonists and Antagonists of NR2F6 Activity in HumansKCL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1856US10030227B2Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytesZANDER THERAPEUTICS INC·Filed 2016·Granted Jul 24, 2018·0 cites·16 claims
- 1956US2022031912A1Quality of a cellular graftSYBLEU INC·Filed 2021·Application pending·0 cites
- 2055US2020071307A1Small molecule agonists and antagonists of nr2f6 activity in animalsZANDER THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2155US2022168240A1Cancer therapy by intratumoral injection of a chemotherapeutic agent in combination with a bioactive immunostimulatory agentSYBLEU INC·Filed 2021·Application pending·0 cites
- 2254US11377442B2Small molecule agonists and antagonists of NR2F6 activityZANDER THERAPEUTICS INC·Filed 2018·Granted Jul 5, 2022·0 cites·4 claims
- 2351US2021403866A1Enhanced dendritic cell immune activation by combined inhibition of nr2f6 with cannibidiolREGEN BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2451US2021059962A1Stimulation of t regulatory cells by cannabidiol as a means of treating arthritis and autoimmunityREGEN BIOPHARMA INC·Filed 2020·Application pending·0 cites
- 2549US2014065096A1Cancer therapy by ex vivo activated autologous immune cellsREGEN BIOPHARMA INC·Filed 2013·Application pending·0 cites
- 2649US2015037303A1Cells, compositions, and treatment methods for stimulation of hematopoiesisREGEN BIOPHARMA INC·Filed 2013·Application pending·0 cites
- 2742US2017166896A1Treatment of Liver Cancer through Embolization Depot Delivery of BORIS Gene Silencing AgentsREGEN BIOPHARMA INC·Filed 2016·Application pending·0 cites
- 2842US2021317180A1Nr2f6 inhibited chimeric antigen receptor cellsREGEN BIOPHARMA INC·Filed 2016·Application pending·0 cites
- 2940US2016074489A1Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturationREGEN BIOPHARMA INC·Filed 2015·Application pending·0 cites
- 3033US2019054118A1Small Molecule Agonists and Antagonists of NR2F6 Activity in AnimalsZANDER THERAPEUTICS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Koos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →